DE60124098D1 - Modofiziertes morbillivirus v proteine - Google Patents

Modofiziertes morbillivirus v proteine

Info

Publication number
DE60124098D1
DE60124098D1 DE60124098T DE60124098T DE60124098D1 DE 60124098 D1 DE60124098 D1 DE 60124098D1 DE 60124098 T DE60124098 T DE 60124098T DE 60124098 T DE60124098 T DE 60124098T DE 60124098 D1 DE60124098 D1 DE 60124098D1
Authority
DE
Germany
Prior art keywords
modoficated
morbillivirus
proteins
morbilliviruses
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60124098T
Other languages
English (en)
Other versions
DE60124098T2 (de
Inventor
L Parks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Wyeth LLC
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC filed Critical Wyeth Holdings LLC
Publication of DE60124098D1 publication Critical patent/DE60124098D1/de
Application granted granted Critical
Publication of DE60124098T2 publication Critical patent/DE60124098T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60124098T 2000-06-23 2001-06-21 Modifiziertes Morbillivirus V Proteine Expired - Lifetime DE60124098T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21365500P 2000-06-23 2000-06-23
US213655P 2000-06-23
PCT/US2001/019806 WO2002000694A2 (en) 2000-06-23 2001-06-21 Modified morbillivirus v proteins

Publications (2)

Publication Number Publication Date
DE60124098D1 true DE60124098D1 (de) 2006-12-07
DE60124098T2 DE60124098T2 (de) 2007-04-05

Family

ID=22795965

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60124098T Expired - Lifetime DE60124098T2 (de) 2000-06-23 2001-06-21 Modifiziertes Morbillivirus V Proteine

Country Status (17)

Country Link
US (1) US6664066B2 (de)
EP (1) EP1292615B1 (de)
JP (1) JP2004513616A (de)
KR (1) KR100885325B1 (de)
CN (1) CN1298738C (de)
AT (1) ATE343589T1 (de)
AU (2) AU6701401A (de)
BR (1) BR0111827A (de)
CA (1) CA2409432C (de)
CY (1) CY1105842T1 (de)
DE (1) DE60124098T2 (de)
DK (1) DK1292615T3 (de)
ES (1) ES2273852T3 (de)
IL (1) IL153004A0 (de)
MX (1) MXPA02012256A (de)
PT (1) PT1292615E (de)
WO (1) WO2002000694A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2340532T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo.
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
CN1871355B (zh) 2003-06-09 2011-12-14 惠氏 从cDNA中回收非节段性负链RNA病毒的改进方法
DE102004042546A1 (de) * 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
EP2046954A2 (de) 2006-07-31 2009-04-15 Curevac GmbH Nukleinsäure der formel (i): gixngn, oder (ii): cixmcn, insbesondere als immunstimulierendes mittel/adjuvans
EP2069485A4 (de) * 2007-07-13 2011-05-25 Medimmune Llc Zubereitung von negativstrang-rna-viren mittels elektroporation
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
MX2010008468A (es) 2008-01-31 2010-08-30 Curevac Gmbh Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CN103025876A (zh) 2010-07-30 2013-04-03 库瑞瓦格有限责任公司 用于转染和免疫刺激的核酸与二硫化物交联的阳离子成分的复合体
EP3578205A1 (de) 2010-08-06 2019-12-11 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
WO2012045082A2 (en) 2010-10-01 2012-04-05 Jason Schrum Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (de) 2011-10-03 2021-12-01 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
DK2791160T3 (da) 2011-12-16 2022-05-30 Modernatx Inc Modificerede mrna-sammensætninger
CN104471064B (zh) * 2012-01-20 2018-11-02 中华人民共和国香港特别行政区政府 副粘病毒及其用途
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX369469B (es) 2013-08-21 2019-11-08 Curevac Ag Vacuna contra el virus respiratorio sincitial.
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
EP3129050A2 (de) 2014-04-01 2017-02-15 CureVac AG Polymerträger-cargo-komplex zur verwendung als immunstimulierendes mittel oder als ein adjuvans
US10458801B2 (en) 2014-05-06 2019-10-29 Uber Technologies, Inc. Systems and methods for travel planning that calls for at least one transportation vehicle unit
US9552559B2 (en) 2014-05-06 2017-01-24 Elwha Llc System and methods for verifying that one or more directives that direct transport of a second end user does not conflict with one or more obligations to transport a first end user
WO2015171772A1 (en) 2014-05-06 2015-11-12 Lord Robert W System and methods for verifying that one or more end user transport directives do not conflict with one or more package delivery directives
ES2813827T3 (es) * 2014-07-18 2021-03-25 Inst Nat Sante Rech Med Péptidos que incluyen un dominio de unión de la subunidad de la fosfoproteína (P) viral a la nucleoproteína (N0) libre de ARN viral
WO2016029168A1 (en) 2014-08-21 2016-02-25 Uber Technologies, Inc. Arranging a transport service for a user based on the estimated time of arrival of the user
US10685416B2 (en) 2015-12-10 2020-06-16 Uber Technologies, Inc. Suggested pickup location for ride services
US10731998B2 (en) 2017-11-05 2020-08-04 Uber Technologies, Inc. Network computer system to arrange pooled transport services

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
EP0932684A2 (de) * 1996-09-27 1999-08-04 American Cyanamid Company Mutationen in der genomischen 3'promoterregion und im polymerasegen, die für die attenuierung von viren der ordnung mononegavirales verantwortlich sind
AU7797798A (en) 1997-05-23 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
KR20010080863A (ko) * 1998-03-26 2001-08-25 윌리암 에이취 캘넌, 에곤 이 버그 마진 바이러스 또는 인간 호흡기 합포체 바이러스서브그룹 비에서 감쇠 담당 돌연변이

Also Published As

Publication number Publication date
MXPA02012256A (es) 2003-04-25
CY1105842T1 (el) 2011-02-02
IL153004A0 (en) 2003-06-24
PT1292615E (pt) 2007-01-31
CN1298738C (zh) 2007-02-07
JP2004513616A (ja) 2004-05-13
ES2273852T3 (es) 2007-05-16
AU6701401A (en) 2002-01-08
WO2002000694A3 (en) 2002-10-10
KR20030032971A (ko) 2003-04-26
AU2001267014B2 (en) 2007-03-15
EP1292615A2 (de) 2003-03-19
WO2002000694A2 (en) 2002-01-03
US20030206925A1 (en) 2003-11-06
BR0111827A (pt) 2003-05-20
CA2409432C (en) 2010-08-03
ATE343589T1 (de) 2006-11-15
DK1292615T3 (da) 2007-02-19
CN1437613A (zh) 2003-08-20
CA2409432A1 (en) 2002-01-03
US6664066B2 (en) 2003-12-16
KR100885325B1 (ko) 2009-02-25
EP1292615B1 (de) 2006-10-25
DE60124098T2 (de) 2007-04-05

Similar Documents

Publication Publication Date Title
ATE343589T1 (de) Modofiziertes morbillivirus v proteine
Sorsa et al. A trypsin‐like protease from Bacteroides gingivalis: partial purification and characterization
DE69935986D1 (de) Streptococcus pneumoniae proteine und nukleinsäuren
ATE321867T1 (de) Zusammensetzungen und methoden zur verwendung von dna polymerasen
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
CY1111006T1 (el) Εκριμματαση ασθενειας alzheimer
BR9914374A (pt) Sequências genÈmicas de neisseria e métodos para seu uso
ATE79138T1 (de) Typenspezifische papillomavirus-dns-sequenzen und peptide.
BR0316435A (pt) Produtos genéticos expressos diferencialmente em tumores e uso dos mesmos
EP1322307A4 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
ATE294855T1 (de) Rna polymerase mutanten mit erhöhter thermostabilität
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE60132190D1 (de) Mutierte version der arginin deiminase
ATE277171T1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
ATE260296T1 (de) Anti-gefrier proteine, deren herstellung und verwendung
ATE255638T1 (de) Nukleotidsequenzen und gegen cycloheximid resistente proteine
WO2001006019A3 (en) Nucleic acids for detecting parvovirus and methods of using same
DE60037413D1 (de) Rekombinante adhesin-proteine aus haemophilus influenzae
PE46999A1 (es) Inhibidores de cicloalquilo de la enzima farnesiltransferasa de las proteinas
WO2003100075A3 (en) Bsnd nucleic acids and proteins
ATE373095T1 (de) Mutierte muskelspezifische enhancer
FR2754822B1 (fr) Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
NO971359L (no) Humant galaktokinase-gen
TR200003184T2 (tr) ''İnsülin benzeri büyüme faktörünü bağlayan proteinin selektif klivajını yapabilen yeni serin proteazı''

Legal Events

Date Code Title Description
8364 No opposition during term of opposition